The strong Q1 beat and rapid early adoption of IMCIVREE in acquired HO (150+ patient start forms in 6 weeks) signal accelerating commercial traction. Watch for upcoming catalysts: Phase 2 PWS data (Q2 2026), RM-718 data (mid-2026), and Japan PMDA decision (H2 2026).
RYTM drugs
RYTM drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 5 $92.31entry
- T+1 · 7mo ago +4.66%α +3.27% · $96.61
- T+5 · 6mo ago −1.08%α −3.07% · $91.31
- T+20 · 6mo ago −8.62%α −13.58% · $84.35
- T+60 · 4mo ago +14.55%α +11.81% · $105.74
Price Chart
How similar events traded
Executive Summary
Rhythm Pharmaceuticals reported Q1 2026 revenue of $60.1M, beating the $56.1M consensus, and an EPS loss of -$0.73, beating the -$0.86 estimate by 15.2%. The beat was driven by strong IMCIVREE sales, including the newly approved acquired hypothalamic obesity indication, but the company's net loss widened to -$56.7M from -$50.8M a year ago, and operating expenses surged 41% YoY.
Key Financial Metrics
Key Facts
- Q1 2026 revenue $60.1M vs consensus $56.1M (beat)
- Q1 2026 EPS -$0.73 vs consensus -$0.86 (15.2% beat)
- IMCIVREE approved by FDA for acquired hypothalamic obesity on March 19, 2026; >150 patient start forms received in first 6 weeks
- European Commission granted Marketing Authorization for IMCIVREE in acquired HO on May 1, 2026
- Net loss widened to -$56.7M from -$50.8M YoY; operating expenses rose to $112.5M from $79.7M
- Cash position $340.6M as of March 31, 2026; company expects sufficient runway for at least 24 months
- Non-GAAP operating expense guidance for FY2026: $385M-$415M
Financial Impact
Revenue beat of $4.0M (7.1%) vs consensus; EPS beat of $0.13 (15.2%) vs consensus; net loss widened by $5.9M YoY
Risk Factors
- Operating expenses growing faster than revenue (41% YoY vs 59% revenue growth)
- EMANATE Phase 3 trial missed primary endpoint in March 2026, creating pipeline uncertainty
- Sequential U.S. revenue declined 5% QoQ due to inventory and insurance transitions
- High cash burn rate ($48.3M in Q1 2026) despite $340.6M cash position
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3287506 |
Track record
26 reports on RYTM
9 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +32.06% at T+60 after the May 1, 2026 report. 10 of 13 went positive at some point.
Filters
- Nov 16, 2026today Press Release Bullish 5/10 Entry $107.48 Now $107.48 +0.00% settles Nov 24
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
- Nov 4, 202612d ago Press Release Bullish 5/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
- Nov 3, 202613d ago 8-K Bullish 6/10 No price data
- Nov 3, 202613d ago Press Release Bullish 6/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
- Nov 2, 202613d ago Press Release Neutral 5/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
- Oct 13, 20264w ago Press Release Bullish 6/10 Entry $86.71 to $88.62 Now $107.48 +23.95% ▲ +2.20% +1.75% vs SPY
- Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $86.61 to $90.20 Now $107.48 +24.10% ▲ +4.14% +5.30% vs SPY
- Sep 14, 20269w ago 144 Bearish 5/10 Entry $96.77 to $99.27 Now $107.48 −11.07% ▼ −2.58% −0.47% vs SPY
- Aug 17, 202613w ago Insider Cluster Bearish 6/10 Entry $115.25 to $113.35 Now $107.48 +6.74% ▲ +1.65% +1.45% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers